ATP-citrate lyase controls endothelial gluco-lipogenic metabolism and vascular inflammation in sepsis-associated organ injury.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
06 07 2023
06 07 2023
Historique:
received:
05
03
2023
accepted:
26
06
2023
revised:
16
06
2023
medline:
10
7
2023
pubmed:
7
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
Sepsis involves endothelial cell (EC) dysfunction, which contributes to multiple organ failure. To improve therapeutic prospects, elucidating molecular mechanisms of vascular dysfunction is of the essence. ATP-citrate lyase (ACLY) directs glucose metabolic fluxes to de novo lipogenesis by generating acetyl-Co-enzyme A (acetyl-CoA), which facilitates transcriptional priming via protein acetylation. It is well illustrated that ACLY participates in promoting cancer metastasis and fatty liver diseases. Its biological functions in ECs during sepsis remain unclear. We found that plasma levels of ACLY were increased in septic patients and were positively correlated with interleukin (IL)-6, soluble E-selectin (sE-selectin), soluble vascular cell adhesion molecule 1 (sVCAM-1), and lactate levels. ACLY inhibition significantly ameliorated lipopolysaccharide challenge-induced EC proinflammatory response in vitro and organ injury in vivo. The metabolomic analysis revealed that ACLY blockade fostered ECs a quiescent status by reducing the levels of glycolytic and lipogenic metabolites. Mechanistically, ACLY promoted forkhead box O1 (FoxO1) and histone H3 acetylation, thereby increasing the transcription of c-Myc (MYC) to facilitate the expression of proinflammatory and gluco-lipogenic genes. Our findings revealed that ACLY promoted EC gluco-lipogenic metabolism and proinflammatory response through acetylation-mediated MYC transcription, suggesting ACLY as the potential therapeutic target for treating sepsis-associated EC dysfunction and organ injury.
Identifiants
pubmed: 37414769
doi: 10.1038/s41419-023-05932-8
pii: 10.1038/s41419-023-05932-8
pmc: PMC10325983
doi:
Substances chimiques
ATP Citrate (pro-S)-Lyase
EC 2.3.3.8
citrate (pro-3S)-lyase
EC 4.1.3.6
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
401Informations de copyright
© 2023. The Author(s).
Références
Cancer Discov. 2019 Mar;9(3):416-435
pubmed: 30626590
Nat Rev Nephrol. 2018 Jul;14(7):417-427
pubmed: 29691495
Curr Opin Lipidol. 2019 Feb;30(1):1-9
pubmed: 30586346
Cell Death Dis. 2022 Feb 17;13(2):159
pubmed: 35177584
J Biol Chem. 2002 Sep 13;277(37):33895-900
pubmed: 12107176
Pharmacol Res. 2019 Aug;146:104292
pubmed: 31167111
Cell Metab. 2022 Jun 7;34(6):919-936.e8
pubmed: 35675800
Cell Metab. 2022 Apr 5;34(4):516-532.e11
pubmed: 35316657
Nat Rev Mol Cell Biol. 2020 Apr;21(4):225-245
pubmed: 31848472
Clin Chest Med. 2016 Jun;37(2):321-31
pubmed: 27229648
Biochem Biophys Res Commun. 2013 Oct 11;440(1):105-11
pubmed: 24051091
Epigenetics. 2009 Aug 16;4(6):399-403
pubmed: 19755853
Cell Metab. 2013 Nov 5;18(5):726-39
pubmed: 24140020
Trends Biochem Sci. 2018 Jan;43(1):61-74
pubmed: 29174173
Exp Mol Med. 2019 Jul 23;51(7):1-13
pubmed: 31337751
J Anesth. 2015 Aug;29(4):635-8
pubmed: 25603734
Trends Mol Med. 2014 Apr;20(4):195-203
pubmed: 24581450
Cell Rep. 2016 Oct 18;17(4):1037-1052
pubmed: 27760311
Nat Rev Cancer. 2008 Dec;8(12):976-90
pubmed: 19029958
Elife. 2016 Feb 19;5:
pubmed: 26894960
Nat Immunol. 2019 Sep;20(9):1186-1195
pubmed: 31384058
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1701-1712
pubmed: 31002870
Cell. 2013 Aug 1;154(3):651-63
pubmed: 23911327
Metabolism. 2016 Oct;65(10):1447-58
pubmed: 27621180
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2):
pubmed: 35046083
Cell. 2018 Oct 4;175(2):502-513.e13
pubmed: 30245009
Exp Mol Med. 2020 Dec;52(12):2005-2019
pubmed: 33311704
Hepatology. 2021 Jan;73(1):160-174
pubmed: 32221968
Eur J Med Chem. 2018 Sep 5;157:1276-1291
pubmed: 30195238
J Clin Invest. 2015 Feb;125(2):665-80
pubmed: 25574840
N Engl J Med. 2019 Mar 14;380(11):1033-1042
pubmed: 30865797
Biochim Biophys Acta. 2014 Sep;1842(9):1579-86
pubmed: 24905734
Front Physiol. 2020 Nov 12;11:580167
pubmed: 33281616
Nat Commun. 2020 Jan 29;11(1):575
pubmed: 31996678
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11278-83
pubmed: 16076959
Nat Commun. 2020 Dec 8;11(1):6296
pubmed: 33293558
Nat Commun. 2016 Oct 25;7:13280
pubmed: 27779186
Antioxidants (Basel). 2021 Apr 08;10(4):
pubmed: 33917812
Crit Care. 2022 Jan 28;26(1):29
pubmed: 35090526
Cells. 2021 Oct 30;10(11):
pubmed: 34831186
Brain Behav Immun. 2014 May;38:77-90
pubmed: 24384468
Trends Cell Biol. 2018 Mar;28(3):224-236
pubmed: 29153487
Biomed Pharmacother. 2020 Aug;128:110226
pubmed: 32460191
Immun Inflamm Dis. 2021 Jun;9(2):389-397
pubmed: 33378581
Metabolism. 2021 Jan;114:154349
pubmed: 32888949
Nature. 2016 Jan 14;529(7585):216-20
pubmed: 26735015
Nat Metab. 2021 Jul;3(7):923-939
pubmed: 34211180
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Cell Metab. 2016 Jul 12;24(1):158-66
pubmed: 27374498
Science. 2009 May 22;324(5930):1076-80
pubmed: 19461003
Inflammation. 2018 Feb;41(1):315-327
pubmed: 29124567
Pharmacol Ther. 2016 Aug;164:144-51
pubmed: 27113407
Nat Commun. 2018 Dec 17;9(1):5357
pubmed: 30559384
Immunity. 2019 Dec 17;51(6):997-1011.e7
pubmed: 31851905
Cell Metab. 2018 Dec 4;28(6):866-880.e15
pubmed: 30146486
Cell Rep. 2013 Nov 14;5(3):654-665
pubmed: 24210820
Crit Care Clin. 2020 Apr;36(2):401-413
pubmed: 32172821
Int J Mol Sci. 2021 Aug 26;22(17):
pubmed: 34502162
Cancer Lett. 2021 Apr 1;502:154-165
pubmed: 33340617
Cell Rep. 2019 May 28;27(9):2772-2784.e6
pubmed: 31141698
Am J Respir Crit Care Med. 2022 Feb 15;205(4):388-396
pubmed: 34715007